Summary
Vaccines have generally been developed with limited insight into their molecular impact. While systems vaccinology, including metabolomics, enables new characterization of vaccine mechanisms of action, these tools have yet to be applied to infants at high risk of infection and receive the most vaccines. Bacille Calmette-Guérin (BCG) protects infants against disseminated tuberculosis (TB) and TB-unrelated infections via incompletely understood mechanisms. We employed mass spectrometry-based metabolomics of blood plasma to profile BCG-induced infant responses in Guinea Bissau in vivo and the U.S. in vitro. BCG selectively altered plasma lipid pathways, including lysophospholipids. BCG-induced lysophosphatidylcholines (LPCs) correlated with both TLR agonist- and purified protein derivative (PPD, mycobacterial antigen)-induced blood cytokine production in vitro, raising the possibility that LPCs contribute to BCG immunogenicity. Analysis of an independent newborn cohort from The Gambia demonstrated shared vaccine-induced metabolites such as phospholipids and sphingolipids. BCG-induced changes to the plasma lipidome and LPCs may contribute to its immunogenicity and inform the discovery and development of early life vaccines.
Highlights
Neonatal BCG immunization generates distinct metabolic shifts in vivo and in vitro across multiple independent cohorts.
BCG induces prominent changes in concentrations of plasma lysophospholipids (LPLs)
BCG induced changes in plasma lysophosphatidylcholines (LPCs) correlate with BCG effects on TLR agonist- and mycobacterial antigen-induced cytokine responses.
Characterization of vaccine-induced changes in metabolism may define predictive signatures of vaccine responses and inform early life vaccine development.
Vaccines have traditionally been developed empirically, with limited insight into their impact on molecular pathways. Metabolomics provides a new approach to characterizing vaccine mechanisms but has not yet been applied to human newborns, who are at the highest risk of infection and receive the most vaccines. Bacille Calmette-Guérin (BCG) prevents disseminated mycobacterial disease in children and can induce broad protection to reduce mortality due to non-TB infections. Underlying mechanisms are incompletely characterized. Employing mass spectrometry-based metabolomics, we demonstrate that early BCG administration alters the human neonatal plasma metabolome, especially lipid metabolic pathways such as lysophosphatidylcholines (LPCs), both in vivo and in vitro. Plasma LPCs correlated with both innate TLR-mediated and PPD antigen-induced cytokine responses suggesting that BCG-induced lipids might contribute to the immunogenicity of this vaccine. Vaccine-induced metabolic changes may provide fresh insights into vaccine immunogenicity and inform the discovery and development of early life vaccines.
Competing Interest Statement
O.L is a named inventor on several Boston Children's Hospital patents relating to human microphysiologic assay systems and vaccine adjuvants. S.M and G.M are employees of Metabolon Inc. The other authors declare no competing financial interests.
Clinical Trial
NCT00625482
Clinical Protocols
Funding Statement
The European Research Council supported the randomized trial of BCG to CB (starting grant ERC2009StG243149), the Danish National Research Foundation (grant DNRF108 to Research Center for Vitamins & Vaccines), and DANIDA, European Union FP7, and OPTIMUNISE (grant Health F32011261375 to the Bandim Health Project); the immunological sub-group study of early BCG vaccination was supported by Novo Nordisk Foundation and a Ph.D. scholarship grant from University of Southern Denmark to KJ; KJ is supported by a grant from Novo Nordisk Foundation (grant NNF14OC0012169). This study was supported by the National Institute of Health/National Institute of Allergy & Infectious Diseases Human Immunology Project Consortium Grant U19AI118608 and Molecular Mechanisms of Combinations Adjuvants Grant U01 AI124284, as well as the BCH Precision Vaccines Program. AA and OL were supported in part via the Mueller Health Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The BCG RCT and the immunological sub-study were approved by the National Committee on Health Ethics of the Ministry of Health in Guinea-Bissau, and a consultative approving statement was obtained from the Danish National Committee on Biomedical Research Ethics. The BCG trial was registered with clinicaltrials.gov, number NCT00625482.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data files for metabolomics and lipidomics were deposited in ImmPort under accession numbers: SDY1376 and SDY1709.
